Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Dysregulated complement pathways are linked to progression from iAMD to advanced AMD, including NVAMD and GA. Higher systemic levels of C4, C4b, and a reduction in C3 are associated with increased ...

Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...